In the last week of the year of the ox (from January 24 to January 28), a total of 12 new shares were listed, which generally brought good returns to the successful investors. According to xingkuang data, the average increase of new shares listed in the last week of the year of the ox on the first day was 45.9%, as shown in the table below:
According to the issuance arrangement, six new shares will be issued next week (February 7-february 11), including three on the main board of Shanghai Stock Exchange, two on the gem and one on the science and innovation board. According to the specific schedule, the subscription will be concentrated on Monday and Wednesday next week. On Monday, you can subscribe for the two stocks of Hefu China and China catalyst science, and on Wednesday, you can subscribe for the two stocks of advertised shares and Biyi shares.
In terms of hot companies, they boast that they focus on nylon pipeline manufacturing and lead the technological innovation of the industry. The company has established a technical R & D Center for automobile nylon pipeline and connection system, which can independently develop nylon pipeline and connections. The growth rate of its revenue and net profit attributable to its parent company are higher than the industry average, and the proportion of R & D investment is lower than the industry average. From 2018 to 2020, the compound growth rate of share revenue and net profit attributable to the parent company was 40.60% and 72.70%, both higher than the average of comparable companies.
list of new share issuance
fundamentals of new shares
Shanghai Stock Exchange main board
Hefu China: the company is mainly a channel provider in the field of medical circulation. It has established cooperative relations with the main in vitro diagnostic reagent projects of more than 100 tertiary hospitals to provide intensive procurement services of in vitro diagnostic products to hospitals. The company’s medical product circulation business is mainly to act as an agent for the original equipment of foreign Innovation Medical Management Co.Ltd(002173) technology, mainly for medical institutions in Greater China. It has successfully acted as an agent and introduced a number of foreign advanced medical equipment, including overseas original accuray, tearscience and viewray. In terms of performance, during the reporting period (January to June 2018, 2019, 2020 and 2021), the net profit attributable to the owner of the parent company was 56 million yuan, 67 million yuan, 73 million yuan and 36 million yuan respectively.
ByI Co., Ltd.: the company is an enterprise mainly engaged in the design, manufacturing and sales of heating kitchen electrical products. The main business of the company mainly includes ODM / OEM business and “Biyi byI” independent brand OBM business. At present, it has cooperated with Philips / Philips, Newell / newway brand, sharkninja / shankoningjia, Delonghi group / Delong company, SEB / Saibo group, Bear Electric Appliance Co.Ltd(002959) Zhejiang Supor Co.Ltd(002032) and other foreign customers. In terms of performance, during the reporting period of the company (January to June 2018, 2019, 2020 and 2021), the deducted non net profits attributable to the owners of the parent company were 40 million yuan, 78 million yuan, 102 million yuan and 52 million yuan respectively.
Jinhui Co., Ltd.: the company is mainly engaged in the mining, beneficiation and trade of non-ferrous metals. Its main products include zinc concentrate, lead concentrate (including silver), etc. The mining rights include two mining rights of Guojiagou lead-zinc mine in Huixian county and the lead-zinc mine in the eastern section of the North ore belt in the South ore belt of Guojiagou mining area in Huixian County, as well as the detailed survey of lead-zinc mine in Jiangkou area of Huixian County, Gansu Province and the detailed survey of huomadi copper mine in Qinzhou District, Tianshui City, Gansu Province. In addition, it owns Lijiagou concentrator. In terms of performance, during the reporting period (2019, 2020 and 2021), the net profit attributable to the owner of the parent company was 162 million yuan, 361 million yuan and 460 million yuan respectively.
gem
Hualan vaccine: the company’s main business is the R & D, production and sales of human vaccines, including influenza virus split vaccine. It is worth mentioning that Hualan vaccine is still the holding subsidiary of the listed company Hualan Biological Engineering Inc(002007) and will still be incorporated into the financial statements of Hualan Biological Engineering Inc(002007) . In terms of performance, during the reporting period (January to June 2018, 2019, 2020 and 2021), the net profit attributable to the owners of the parent company was 212 million yuan, 358 million yuan, 899 million yuan and – 42 million yuan respectively.
Flaunting shares: the company’s main business is the R & D, production and sales of a series of products such as automobile nylon pipes and connectors. The main products include power system connecting pipes, etc. As one of the few advantageous enterprises in China that have entered the supply system of joint venture brand vehicle manufacturers, the company’s main products have been widely matched with many models of well-known brands such as Volkswagen, Audi, Skoda, Datong, Ford and Peugeot, and has established stable strategic cooperative relations with well-known vehicle manufacturers and excellent auto parts manufacturers in China, It has a high brand awareness and industry position in the automobile nylon pipeline manufacturing industry. In terms of performance, during the reporting period (January to June 2018, 2019, 2020 and 2021), the net profit attributable to the owners of the parent company was 41 million yuan, 88 million yuan, 121 million yuan and 48 million yuan respectively.
scientific innovation board
China catalyst section: the company is mainly engaged in the R & D, production and sales of special molecular sieves and new catalytic materials, as well as chemical technology and chemical process services. The main products are special molecular sieve and catalyst, non molecular sieve catalyst, catalytic application process and chemical technology services. The application fields include environmental protection, energy and chemical industry, among which special molecular sieve and catalyst are the main source of income of the company. In terms of performance, during the reporting period of the company (January to June 2018, 2019, 2020 and 2021), the deducted non net profits attributable to the owners of the parent company were RMB 05 million, RMB 53 million, RMB 86 million and RMB 84 million respectively.
